Last reviewed · How we verify
Alka-Seltzer Gold (GOLD)
Alka-Seltzer Gold, marketed by Bayer HealthCare LLC, is a well-established over-the-counter heartburn relief medication. Its key strength lies in its rapid action to neutralize stomach acid, providing quick relief to consumers. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | GOLD |
|---|---|
| Sponsor | Bayer HealthCare LLC. |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Heartburn Relief
- Acid Indigestion Relief
- Sour Stomach Relief
Common side effects
Key clinical trials
- Goat Milk-Derived Formula vs. Undiluted Goat Milk in Infants Unable to Exclusively Breastfeed: Growth and Biomarker Analysis (NA)
- Detection of CardioRespiratory Events Using Acoustic Monitoring in Preterm Infants on CPAP
- Group-Based Exercise Intervention to Prevent Cognitive and Motor Decline (NA)
- Adaptation and RCT of Written Exposure Therapy for Adolescents (NA)
- Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performance of Children With Cerebral Palsy (NA)
- Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- Evaluation of Accuracy of 3D Printed Aligners in Comparison to Thermoformed Aligners in Orthodontic Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alka-Seltzer Gold CI brief — competitive landscape report
- Alka-Seltzer Gold updates RSS · CI watch RSS
- Bayer HealthCare LLC. portfolio CI